SCHEMBL732303

SCHEMBL732303

COC(=O)C(C)(C)c1ccc(Cl)c([N+](=O)[O-])c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.49
LMNA P02545 5/20 0.49
MAPT P10636 4/20 0.49
ALDH1A1 P00352 2/20 0.49
HPGD P15428 2/20 0.49
MAPK1 P28482 2/20 0.49
RAF1 P04049 1/20 0.49
GFER P55789 1/20 0.49
PAX8 Q06710 1/20 0.49
VCAM1 P19320 3/20 0.49
HSP90AA1 P07900 1/20 0.47
NPSR1 Q6W5P4 3/20 0.47
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
POLB P06746 1/20 0.44
XBP1 P17861 1/20 0.44
HTT P42858 2/20 0.44
CNR1 P21554 1/20 0.44
CNR2 P34972 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6821981 0.84 VCAM1 (0.53) LMNAMAPTALDH1A1HPGDMAPK1
SCHEMBL20302045 0.83 NPSR1 (0.47) LMNAMAPTALDH1A1HPGDMAPK1
SCHEMBL6981667 0.83 KMT2A (0.51) LMNAMAPTALDH1A1HPGDNPSR1
SCHEMBL4857830 0.83 ALDH1A1 (0.49) LMNAMAPTALDH1A1HPGDMAPK1
SCHEMBL4854941 0.80 NPSR1 (0.47) LMNAMAPTALDH1A1HPGDMAPK1
SCHEMBL15456899 0.80 CHEK1 (0.49) LMNAALDH1A1HPGDNPSR1KMT2A
SCHEMBL4856254 0.80 NPSR1 (0.47) ALDH1A1HPGDMAPK1VCAM1NPSR1
SCHEMBL1627157 0.80 CNR1 (0.51) MAPTHPGDRAF1POLBCNR1
SCHEMBL18562538 0.79 NPSR1 (0.46) MAPTALDH1A1HPGDMAPK1NPSR1
SCHEMBL7652330 0.79 SIRT6 (0.50) LMNAMAPTALDH1A1HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250042870-A1 DP ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2025-02-06 US disclosed
EP-3854781-B1 DP ANTAGONISTS ONO PHARMACEUTICAL CO (JP) 2024-05-22 EP disclosed
US-20220204468-A1 DP ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2022-06-30 US disclosed
US-11319296-B2 DP antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2022-05-03 US disclosed
US-20220033371-A1 DP ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2022-02-03 US disclosed
EP-3854781-A1 DP ANTAGONIST ONO Pharmaceutical Co., Ltd. (JP) 2021-07-28 EP disclosed
WO-2020059790-A1 DP ANTAGONIST 小野薬品工業株式会社 2020-03-26 WO disclosed
EP-1666473-B1 CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2013-01-02 EP disclosed
US-8138335-B2 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD (JP) 2012-03-20 US disclosed
US-20100029631-A1 CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2010-02-04 US disclosed
US-7601712-B2 Such as (1)-2-(4-chloro-3-((2-chloro-4-(((2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-ly)methoxy)benzoyl)amino)phenyl)-2-methylpropanoic acid; prostaglandin receptor agonists ONO PHARMACEUTICAL CO., LTD. (JP) 2009-10-13 US disclosed
US-20070004716-A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-01-04 US disclosed
CN-1882554-A Carboxylic acid compounds and pharmaceutical compositions containing them as active ingredient ONO PHARMACEUTICAL CO (JP) 2006-12-20 CN disclosed
EP-1666473-A1 CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2006-06-07 EP disclosed
CN-1221538-C Calcium salts of 1,5-benzodiazepine derivatives, process for producing salts and drugs containing same ZERIA NEW PHARMACEUTICAL CO LT (JP) 2005-10-05 CN disclosed
EP-1234818-B1 CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME ZERIA PHARM CO LTD (JP) 2004-09-08 EP disclosed
US-6747022-B2 TREATING DIGESTIVE TRACT DISEASE RESULTING FROM EXCESSIVE SECRETION OF GASTRIC ACID ZERIA PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20030096809-A1 Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same ZERIA PHARMACEUTICAL CO., LTD. (JP) 2003-05-22 US disclosed
CN-1409706-A Calcium salt of 1, 5-benzodiazepine * derivative, process for preparing the salt and pharmaceutical containing the salt ZERIA PHARM CO LTD (JP) 2003-04-09 CN disclosed
EP-1234818-A1 CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME Zeria Pharmaceutical Co., Ltd. (JP) 2002-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220033371-A1 DP ANTAGONIST OPRL1, CNR1, NPSR1 THRB 785/4885LMNA 2947/4885MAPT 3282/4885
US-20100029631-A1 CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT GPR17, CYSLTR1, KIT THRB 1586/4885LMNA 4266/4885MAPT 1750/4885
US-20030096809-A1 Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same CCKBR, CCKAR, GABRB1 THRB 290/4885LMNA 2877/4885MAPT 4232/4885
US-20220204468-A1 DP ANTAGONIST OPRL1, CNR1, NPSR1 THRB 785/4885LMNA 2947/4885MAPT 3282/4885
US-20070004716-A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient GPR17, CYSLTR1, KIT THRB 1586/4885LMNA 4266/4885MAPT 1750/4885
US-11319296-B2 DP antagonist OPRL1, CNR1, NPSR1 THRB 785/4885LMNA 2947/4885MAPT 3282/4885
US-20250042870-A1 DP ANTAGONIST OPRL1, CNR1, NPSR1 THRB 785/4885LMNA 2947/4885MAPT 3282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.